Previous 10 | Next 10 |
Expected to add $33 million in cash at closing to Equillium’s balance sheet and extend operating runway into 2024 Acquisition includes novel drug candidate MET642, an orally delivered Phase 2 ready FXR agonist for ulcerative colitis Preston Klassen, M.D., MH...
The following slide deck was published by Equillium, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Equillium, Inc. 2022 Q2 - Results - Earnings Call Presentation
Equillium press release ( NASDAQ: EQ ): Q2 GAAP EPS of -$0.41 in-line. Cash, cash equivalents and short-term investments totaled $57.6 million as of June 30, 2022, compared to $68.8 million as of March 31, 2022. For further details see: Equillium GAAP EPS of -$0....
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the second quarter 2022 and provided an update on its c...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced a presentation at the 3rd Annual Cytokine-Based Drug Development Summit. The ...
Gainers: Inspira Technologies Oxy ( IINN ) +98% . Cano Health CANO +18% . Veru VERU +16% . Amylyx Pharmaceuticals ( AMLX ) +13% . Equillium ( EQ ) +12% . Losers: Applied Molecular Transport AMTI -26% . HTG Molecular D...
Equillium press release (NASDAQ:EQ): Q1 GAAP EPS of -$1.17. Cash and cash equivalents of $68.83M For further details see: Equillium GAAP EPS of -$1.17
Initiated EQUATOR Phase 3 study of itolizumab in first-line aGVHD Acquired Bioniz Therapeutics, adding two first-in-class clinical-stage assets to pipeline and proprietary product discovery platform Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that the European Hematology Association (EHA) has published an abstract high...
Itolizumab-induced reduction of CD6 from T effector cells promotes the development and activity of T regulatory cells CD6-ALCAM pathway confirmed as a target to prevent pathogenic T cell recruitment into inflamed organs Equillium, Inc. (Nasdaq: EQ), a clinical-stage ...
News, Short Squeeze, Breakout and More Instantly...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will be participating in the Leerink Partners Therapeutic Forum: I&I and Metabolism, as well as the Jone...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effe...
A look at the top 10 most actives in the United States SOBR Safe Inc. (SOBR) rose 74.6% to $0.46 on volume of 265,324,361 shares MicroAlgo Inc. (MLGO) rose 669.9% to $12.01 on volume of 183,977,846 shares PROSHARES TRUST (SQQQ) fell 0.7% to $9.86 on volume of 124,114,596 shares Faraday ...